Marcia A Munoz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1246095/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages. ELife, 2021, 10, .	6.0	9
2	Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone, 2020, 139, 115493.	2.9	86
3	Bisphosphonates and Bone Cells—Molecular Mechanisms. , 2020, , 565-578.		1
4	Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Frontiers in Immunology, 2019, 10, 1900.	4.8	21
5	Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes. Journal of Allergy and Clinical Immunology, 2019, 143, 2315-2317.e3.	2.9	15
6	From vesicle to cytosol. ELife, 2018, 7, .	6.0	6
7	Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. Journal of Allergy and Clinical Immunology, 2017, 140, 873-875.e6.	2.9	29
8	Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases. Immunology and Cell Biology, 2016, 94, 994-999.	2.3	36
9	A highly sensitive prenylation assay reveals <i>in vivo</i> effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. Small GTPases, 2015, 6, 202-211.	1.6	33
10	The E3 Ubiquitin Ligase EDD Regulates S-Phase and G ₂ /M DNA Damage Checkpoints. Cell Cycle, 2007, 6, 3070-3077.	2.6	56